John Miners

h-index

Research activity per year

Research Biography

Professor Miners was a Postdoctoral Research Scientist at Oxford University before taking up a position as Toxicologist in the Department of Biochemistry and Chemical Pathology of Flinders Medical Centre in 1977. He joined the Department of Clinical Pharmacology in 1978. Until 2002 Prof Miners held the positions of Chief Pharmacologist and Professor in Clinical Pharmacology. From 2003 to 2013, he was Professor and Head of the Department of Clinical Pharmacology. He currently holds a part-time research only position as Professor of Pharmacology and Therapeutics.

Research Interests

Drug and chemical metabolism in humans, particularly sources of variability in drug elimination and its pharmacokinetic and therapeutic consequences. Current interests include:

Structure-function relationships and genetic polymorphisms of human UDP-glucuronosyltransferases and cytochromes P450
In vitro (in vitro-in vivo extrapolation) and computational models for the prediction of drug and chemical metabolism parameters in vivo
Drug-drug interactions
Metabolomics (including biomarkers of drug response)
Therapeutic drug monitoring

Completed Supervisions

Principal Supervisions:

Pharmacology and Therapeutics (20)

Supervision

Registered

Research Areas

Medical biosciences

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

SDG 3 Good Health and Well-being
SDG 4 Quality Education
SDG 7 Affordable and Clean Energy

Fingerprint

Dive into the research topics where John Miners is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

246 Article
50 Paper
16 Review article
11 Meeting Abstract
More

Reply to “Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data”
Miners, J. O. & Polasek, T. M., Mar 2026, In: Clinical Pharmacology and Therapeutics. 119, 3, p. 587 1 p.
Research output: Contribution to journal › Letter › peer-review
UDP-Glycosyltransferases
Hulin, J. A., Hu, D. G., Miners, J. O., Mackenzie, P. I. & Meech, R., 2026, Comprehensive Toxicology. McLean, C. A. (ed.). 4th ed. Elsevier, p. 578-607 30 p.
Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
Caution with PBPK modeling based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: commentary on Dong et al.
Miners, J. O. & Polasek, T. M., Aug 2025, In: Clinical Pharmacology and Therapeutics. 118, 2, p. 301-303 3 p.
Research output: Contribution to journal › Comment/debate

Open Access
File
2 Citations (Scopus)

12 Downloads (Pure)
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance
Miners, J. O., Polasek, T. M., Hulin, J. A., Rowland, A. & Meech, R., Aug 2023, In: Pharmacology and Therapeutics. 248, 58 p., 108459.
Research output: Contribution to journal › Review article › peer-review
52 Citations (Scopus)
The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation
Nair, P. C., Burns, K., Chau, N., McKinnon, R. A. & Miners, J. O., Dec 2023, In: Journal of Biological Chemistry. 299, 12, 17 p., 105368.
Research output: Contribution to journal › Article › peer-review

Open Access
File
2 Citations (Scopus)

60 Downloads (Pure)

Kinetic characterisation of S-naproxen glucuronidation by human kidney cortical microsomes and recombinant UGT 1A9 and UGT2B7
Knights, K. (Speaker), Gaganis, V. (Speaker), Burns, K. (Speaker), Elliot, D. (Speaker) & Miners, J. (Speaker)
1 Jan 2004
Activity: Talk or presentation types › Oral presentation
NSAID-arachidonic acid interactions are intimately linked to the nephrotoxic potential of NAIDs during renal ischaemia
Gaganis, V. (Speaker), Miners, J. (Speaker) & Knights, K. (Speaker)
30 Nov 2003
Activity: Talk or presentation types › Oral presentation
Unsaturated fatty acids: potent inhibitors of renal UDP-glucuronosyltransferases (UGT)
Gaganis, V. (Speaker), Sallustio, B. (Speaker), Miners, J. (Speaker) & Knights, K. (Speaker)
19 Aug 2003
Activity: Talk or presentation types › Oral presentation
Fatty acids are potent inhibitors of 4-methylumbelliferone glucuronidation by human renal and recombinant UDP-glucuronosyltransferases
Gaganis, V. (Speaker), Miners, J. (Speaker), Knights, K. (Speaker) & Sallustio, B. (Speaker)
7 Jul 2002
Activity: Talk or presentation types › Oral presentation
Role of fatty acids as substrates for renal UDP-glucuronosyltransferases and inhibitors of 4-methylumbelliferone glucuronidation by human kidney cortical microsomes
Gaganis, V. (Speaker), Sallustio, B. (Speaker), Miners, J. (Speaker) & Knights, K. (Speaker)
3 Dec 2001
Activity: Talk or presentation types › Oral presentation

Professor John Miners

Personal profile

Research Biography

Research Interests

Completed Supervisions

Supervision

Research Areas

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Reply to “Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data”

UDP-Glycosyltransferases

Caution with PBPK modeling based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: commentary on Dong et al.

Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance

The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation

Kinetic characterisation of S-naproxen glucuronidation by human kidney cortical microsomes and recombinant UGT 1A9 and UGT2B7

NSAID-arachidonic acid interactions are intimately linked to the nephrotoxic potential of NAIDs during renal ischaemia

Unsaturated fatty acids: potent inhibitors of renal UDP-glucuronosyltransferases (UGT)

Fatty acids are potent inhibitors of 4-methylumbelliferone glucuronidation by human renal and recombinant UDP-glucuronosyltransferases

Role of fatty acids as substrates for renal UDP-glucuronosyltransferases and inhibitors of 4-methylumbelliferone glucuronidation by human kidney cortical microsomes

Professor John Miners

Personal profile

Research Biography

Research Interests

Completed Supervisions

Supervision

Research Areas

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Research output

Activities